S
Shigeto Tohma
Researcher at Meiji Pharmaceutical University
Publications - 182
Citations - 4934
Shigeto Tohma is an academic researcher from Meiji Pharmaceutical University. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 31, co-authored 161 publications receiving 4251 citations.
Papers
More filters
Journal ArticleDOI
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis.
Akari Suzuki,Ryo Yamada,Xiaotian Chang,Shinya Tokuhiro,Tetsuji Sawada,Masakatsu Suzuki,Miyuki Nagasaki,Makiko Nakayama-Hamada,Reimi Kawaida,Mitsuru Ono,Masahiko Ohtsuki,Hidehiko Furukawa,Shinichi Yoshino,Masao Yukioka,Shigeto Tohma,Tsukasa Matsubara,Shigeyuki Wakitani,Ryota Teshima,Yuichi Nishioka,Akihiro Sekine,Aritoshi Iida,Atsushi Takahashi,Tatsuhiko Tsunoda,Yusuke Nakamura,Kazuhiko Yamamoto +24 more
TL;DR: The results imply that the PADI4 haplotype associated with susceptibility to rheumatoid arthritis increases production of citrullinated peptides acting as autoantigens, resulting in heightened risk of developing the disease.
Journal ArticleDOI
Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population
Yukinori Okada,Chikashi Terao,Katsunori Ikari,Yuta Kochi,Koichiro Ohmura,Akari Suzuki,Takahisa Kawaguchi,Eli A. Stahl,Eli A. Stahl,Fina A S Kurreeman,Fina A S Kurreeman,Fina A S Kurreeman,Nao Nishida,Hiroko Ohmiya,Keiko Myouzen,Meiko Takahashi,Tetsuji Sawada,Yuichi Nishioka,Masao Yukioka,Tsukasa Matsubara,Shigeyuki Wakitani,Ryota Teshima,Shigeto Tohma,Kiyoshi Takasugi,Kota Shimada,Akira Murasawa,Shigeru Honjo,Keitaro Matsuo,Hideo Tanaka,Kazuo Tajima,Taku Suzuki,Takuji Iwamoto,Yoshiya Kawamura,Hisashi Tanii,Yuji Okazaki,Tsukasa Sasaki,Peter K. Gregersen,Leonid Padyukov,Jane Worthington,Katherine A. Siminovitch,Mark Lathrop,Atsuo Taniguchi,Atsushi Takahashi,Katsushi Tokunaga,Michiaki Kubo,Yusuke Nakamura,Naoyuki Kamatani,Tsuneyo Mimori,Robert M. Plenge,Robert M. Plenge,Hisashi Yamanaka,Shigeki Momohara,Ryo Yamada,Fumihiko Matsuda,Kazuhiko Yamamoto +54 more
TL;DR: This study identified nine loci newly associated with rheumatoid arthritis at a threshold of P < 5.0 × 10−8, including B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.
Journal ArticleDOI
Disease Activity Score 28 (DAS28) using C‐reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan
Toshihiro Matsui,Yoshiaki Kuga,Atsushi Kaneko,Jinju Nishino,Yoshito Eto,Noriyuki Chiba,Masayuki Yasuda,Koichiro Saisho,Kota Shimada,Shigeto Tohma +9 more
TL;DR: DAS28-CRP significantly underestimated disease activity and overestimated the improvement in disease activity compared with DAS 28-ESR, and should be evaluated using different criteria from that for DAS28 -ESR.
Journal ArticleDOI
Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety
Yukiko Komano,Michi Tanaka,Toshihiro Nanki,Ryuji Koike,Ryoko Sakai,Hideto Kameda,Atsuo Nakajima,Kazuyoshi Saito,Mitsuhiro Takeno,Tatsuya Atsumi,Shigeto Tohma,Satoshi Ito,Naoto Tamura,Takao Fujii,Tetsuji Sawada,Hiroaki Ida,Akira Hashiramoto,Takao Koike,Yoshiaki Ishigatsubo,Katsumi Eguchi,Yoshiya Tanaka,Tsutomu Takeuchi,Nobuyuki Miyasaka,Masayoshi Harigai +23 more
TL;DR: This study has provided the first epidemiological data on Japanese patients with RA for the safety of TNF inhibitors compared to nonbiological DMARD for up to 1 year of treatment and found that anti-TNF therapy was associated with a significantly increased risk for serious infections, compared to treatment with nonbiologists.
Journal ArticleDOI
Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
Atsushi Ogata,Kazuhide Tanimura,Toyohiko Sugimoto,Hiroshi Inoue,Yukitomo Urata,Tsukasa Matsubara,Masakazu Kondo,Yukitaka Ueki,Mitsuhiro Iwahashi,Shigeto Tohma,Shuji Ohta,Yukihiko Saeki,Toshio Tanaka +12 more
TL;DR: To evaluate the efficacious noninferiority of subcutaneous tocilizumab injection to intravenous TCZ infusion monotherapy in Japanese patients with rheumatoid arthritis with an inadequate response to synthetic and/or biologic disease‐modifying antirheumatic drugs (DMARDs).